Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome

Blood

Volumn 131, Issue 13, 2018, Pages 1442-1455

  Weiss, Eric S ^a   Girard Guyonvarc’h, Charlotte ^b   Holzinger, Dirk ^c,d   De Jesus, Adriana A ^e   Tariq, Zeshan ^f   Picarsic, Jennifer ^a   Schiffrin, Eduardo J ^g   Foell, Dirk ^c   Grom, Alexei A ^h   Ammann, Sandra ⁱ   Ehl, Stephan ⁱ   Hoshino, Tomoaki ^j   Goldbach Mansky, Raphaela ^e   Gabay, Cem ^b   Canna, Scott W ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e National Institute of Allergy and Infectious Diseases   (United States)

^f NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^g Transitec Consulting Engineers   (Switzerland)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CRYOPYRIN; CXCL9 CHEMOKINE; FERRITIN; GAMMA INTERFERON; INFLAMMASOME; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; APOPTOSIS REGULATORY PROTEIN; CALCIUM BINDING PROTEIN; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; IL1B PROTEIN, HUMAN; IL1B PROTEIN, MOUSE; INTERLEUKIN 1BETA; INTERLEUKIN-18 BINDING PROTEIN; IPAF PROTEIN, MOUSE; MEFV PROTEIN, HUMAN; MEFV PROTEIN, MOUSE; NLRC4 PROTEIN, HUMAN; NLRP3 PROTEIN, HUMAN; NLRP3 PROTEIN, MOUSE; PYRIN; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOTOXIC LYMPHOCYTE; DISEASE ACTIVITY; DISEASE SEVERITY; DNA LIBRARY; GERMLINE MUTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERACTIVITY; INTESTINE EPITHELIUM; LYMPHOCYTOPOIESIS; MACROPHAGE ACTIVATION SYNDROME; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; TURNOVER TIME; UPREGULATION; AMINO ACID SUBSTITUTION; ANIMAL; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; KNOCKOUT MOUSE; MISSENSE MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CALCIUM-BINDING PROTEINS; CARD SIGNALING ADAPTOR PROTEINS; HUMANS; INFLAMMASOMES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME; MICE; MICE, KNOCKOUT; MUTATION, MISSENSE; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PYRIN; SIGNAL TRANSDUCTION;

EID: 85046850685     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-12-820852     Document Type: Article

References (65)

1. Weaver LK, Behrens EM. Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol. 2014;26(5):562-569.
2. Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275-281.
3. Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, et al; Hellenic Sepsis Study Group. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. 2017;15(1):172.
4. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518.
5. Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. Blood. 2011;118(3):618-626.
6. Sepulveda FE, Maschalidi S, Vosshenrich CA, et al. A novel immunoregulatory role for NK-cell cytotoxicity in protection from HLH-like immunopathology in mice. Blood. 2015; 125(9):1427-1434.
7. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD81 T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735-743.
8. Pachlopnik Schmid J, Ho CH, Chrétien F, et al. Neutralization of IFNgamma defeats haemo-phagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med. 2009;1(2):112-124.
9. Crozat K, Hoebe K, Ugolini S, et al. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis [published correction appears in J Exp Med. 2008;205(3):737]. J Exp Med. 2007; 204(4):853-863.
10. Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(1) T cells and dendritic cells. Blood. 2013;121(26):5184-5191.
11. Bracaglia C, de Graaf K, Pires Marafon D, et al. Elevated circulating levels of interferon-g and interferon-g-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76(1): 166-172.
12. Kaufman KM, Linghu B, Szustakowski JD, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2014;66(12):3486-3495.
13. Schulert GS, Zhang M, Fall N, et al. Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. J Infect Dis. 2016;213(7):1180-1188.
14. Villanueva J, Lee S, Giannini EH, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther. 2005;7(1):R30-R37.
15. Mandal A, Viswanathan C. Natural killer cells: in health and disease. Hematol Oncol Stem Cell Ther. 2015;8(2):47-55.
16. Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/ macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med. 2009;10(3):387-392.
17. Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
18. Henter JI, Samuelsson-Horne A, Aricò M, et al; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7): 2367-2373.
19. Minoia F, Davì S, Horne A, et al; Histiocyte Society. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014; 66(11):3160-3169.
20. Chellapandian D, Das R, Zelley K, et al; EBV-HLH Rituximab Study Group. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162(3):376-382.
21. Pay S, Türkçapar N, Kalyoncu M, et al; Ankara Rheumatology Study Group. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25(5): 639-644.
22. Ombrello MJ, Arthur VL, Remmers EF, et al; British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group, Inception Cohort of Newly Diagnosed Patients with Juvenile Idiopathic Arthritis (ICON-JIA) Study Group, Childhood Arthritis Prospective Study (CAPS) Group, Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators, Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group, Biologically Based Outcome Predictors in JIA (BBOP) Group. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis. 2017;76(5):906-913.
23. Lequerré T, Quartier P, Rosellini D, et al; Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67(3):302-308.
24. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545-555.
25. De Benedetti F, Brunner HI, Ruperto N, et al; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385-2395.
26. de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol. 2015;33(1):823-874.
27. Canna SW, de Jesus AA, Gouni S, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140-1146.
28. Romberg N, Al Moussawi K, Nelson-Williams C, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46(10):1135-1139.
29. Liang J, Alfano DN, Squires JE, et al. Novel NLRC4 mutation causes a syndrome of perinatal autoinflammation with hemophagocytic lymphohistiocytosis, hepatosplenomegaly, fetal thrombotic vasculopathy, and congenital anemia and ascites. Pediatr Dev Pathol. 2017; 20(6):498-505.
30. Canna SW, Girard C, Malle L, et al. Life-threatening NLRC4-associated hyper-inflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017; 139(5):1698-1701.
31. Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin Immunol. 2013;25(6):439-448.
32. Shimizu M, Nakagishi Y, Inoue N, et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol. 2015;160(2):277-281.
33. Mazodier K, Marin V, Novick D, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood. 2005;106(10):3483-3489.
34. Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011;121(6):2264-2277.
35. Strippoli R, Carvello F, Scianaro R, et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. 2012;64(5): 1680-1688.
36. Chae JJ, Cho YH, Lee GS, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1b activation and severe autoinflammation in mice. Immunity. 2011;34(5):755-768.
37. Nowarski R, Jackson R, Gagliani N, et al. Epithelial IL-18 equilibrium controls barrier function in colitis. Cell. 2015;163(6): 1444-1456.
38. Ayres JS, Trinidad NJ, Vance RE. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med. 2012;18(5): 799-806.
39. Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013;38(4):792-804.
40. Bufler P, Azam T, Gamboni-Robertson F, et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci USA. 2002;99(21): 13723-13728.
41. Biancotto A, Feng X, Langweiler M, Young NS, McCoy JP. Effect of anticoagulants on multiplexed measurement of cytokine/ chemokines in healthy subjects. Cytokine. 2012;60(2):438-446.
42. Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology (Oxford). 2016;55(12):2237-2247.
43. Petty RE, Southwood TR, Manners P, et al; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2): 390-392.
44. Ravelli A, Minoia F, Davì S, et al; Histiocyte Society. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68(3):566-576.
45. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355(6): 581-592.
46. Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford). 2010; 49(9):1645-1653.
47. Brydges SD, Broderick L, McGeough MD, Pena CA, Mueller JL, Hoffman HM. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest. 2013;123(11):4695-4705.
48. Kitamura A, Sasaki Y, Abe T, Kano H, Yasutomo K. An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med. 2014;211(12):2385-2396.
49. Levy M, Thaiss CA, Zeevi D, et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell. 2015;163(6): 1428-1443.
50. Rauch I, Deets KA, Ji DX, et al. NAIP-NLRC4 inflammasomes coordinate intestinal epithelial cell expulsion with eicosanoid and IL-18 release via activation of caspase-1 and -8. Immunity. 2017;46(4):649-659.
51. Man SM, Hopkins LJ, Nugent E, et al. Inflammasome activation causes dual recruitment of NLRC4 and NLRP3 to the same macromolecular complex. Proc Natl Acad Sci USA. 2014;111(20):7403-7408.
52. Qu Y, Misaghi S, Newton K, et al. NLRP3 recruitment by NLRC4 during Salmonella infection. J Exp Med. 2016;213(6):877-885.
53. Pabst C, Bergeron A, Lavallée VP, et al. GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. Blood. 2016;127(16):2018-2027.
54. Yan DW, Li DW, Yang YX, et al. Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery. Br J Cancer. 2010;103(7): 961-969.
55. Brydges SD, Mueller JL, McGeough MD, et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity. 2009;30(6):875-887.
56. Novick D, Schwartsburd B, Pinkus R, et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine. 2001;14(6):334-342.
57. Lehmberg K, Pink I, Eulenburg C, Beutel K, Maul-Pavicic A, Janka G. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr. 2013;162(6):1245-1251.
58. Put K, Vandenhaute J, Avau A, et al. Inflammatory gene expression profile and defective interferon-g and granzyme K in natural killer cells from systemic juvenile idiopathic arthritis patients. Arthritis Rheumatol. 2017;69(1):213-224.
59. Thelemann C, Eren RO, Coutaz M, et al. Interferon-g induces expression of MHC class II on intestinal epithelial cells and protects mice from colitis. PLoS One. 2014;9(1):e86844.
60. Hepworth MR, Monticelli LA, Fung TC, et al. Innate lymphoid cells regulate CD41 T-cell responses to intestinal commensal bacteria. Nature. 2013;498(7452):113-117.
61. Volker-Touw CM, de Koning HD, Giltay JC, et al. Erythematous nodes, urticarial rash and arthral-gias in a large pedigree with NLRC4-related autoinflammatory disease, expansion of the phenotype. Br J Dermatol. 2017;176(1): 244-248.
62. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957-1959.
63. Heng TS, Painter MW; Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol. 2008;9(10): 1091-1094.
64. Su AI, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA. 2004; 101(16):6062-6067.
65. McCall MN, Uppal K, Jaffee HA, Zilliox MJ, Irizarry RA. The Gene Expression Barcode: leveraging public data repositories to begin cataloging the human and murine transcriptomes. Nucleic Acids Res. 2011;39(Database issue suppl_1): D1011-D1015.